Vibrotactile Foot Device for Freezing of Gait in Parkinson's Disease
- Conditions
- Freezing of GaitParkinson Disease
- Registration Number
- NCT06147713
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Brief Summary
Freezing of gait (FOG) is a common, disabling symptom of later stage Parkinson's disease (PD), and can induce significant morbidity and mortality by increasing risk of falls as the disease progresses. Despite optimum medical management and deep brain stimulation therapy, many patients with PD are incapacitated by FOG and gait disorders. Non-invasive vibrotactile stimulation has been reported to potentially improve FOG of patients with PD. However, results of studies were variable, and there is a lack of convenient vibrotactile devices ready for daily use with reliable clinical trial data. In the proposed study, the investigator will test the effect of a newly developed vibrotactile foot device (Smart shoe) on participants diagnosed with PD and FOG. EEG and fMRI are obtained in order to investigate the underlying neurological mechanism.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Age 30-80 years
- Diagnosed with Parkinson's Disease according to MDS Clinical Diagnostic Criteria
- Stable drug therapy without any change in the past one month
- Subjective presence of FOG more than once per day
- Objective presence of FOG by provoking tasks, e.g., gait initiation, rapid full turn, et al.
- Able to walk unaided at least 20 meters
- Provide written informed consent
- Stroke and other diseases interfering ambulation
- Severe foot sensory impairments disabling the individual to perceive vibratory stimulation
- History of deep brain stimulation surgery
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method New Freezing of Gait Questionnaire (NFOGQ) 2 weeks Changes in the New Freezing of Gait Questionnaire (NFOGQ) score
Freezing severity 2 weeks Changes in the quantified freezing severity during walking task, videotape reviewed by movement disorder specialists
- Secondary Outcome Measures
Name Time Method Quantitative Gait parameters 2 weeks Changes in gait parameters such as stride length, et al. during walking tasks
Number of falls and near falls 2 weeks Changes in number of falls and near falls during intervention period
Berg Balance Scale 2 weeks Changes in the Berg Balance Scale score
Clinical Global Impressions Scale (CGI-I) 2 weeks Changes in the Clinical Global Impressions Scale (CGI-I) score
39-item Parkinson's Disease Questionnaire (PDQ-39) 2 weeks Changes in the 39-item Parkinson's Disease Questionnaire (PDQ-39) score
MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III 2 weeks Changes in the MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III score
Trial Locations
- Locations (1)
Xuanwu Hospital
🇨🇳Beijing, China
Xuanwu Hospital🇨🇳Beijing, ChinaPiu Chan, MD.,PhD.Contact+86-010-83198677pbchan@hotmail.com